AbCellera Biologics Inc.

seen any kind of impact on the business development front. And, you know, I guess whether or not you think that the model that you guys provide to a potential company is more attractive in a liquidity-constrained environment than perhaps it is when things are better.

Thanks, Steve Perel here. Yeah, so, you know, obviously it's been trying times in the market. As As mentioned on the comments, our business is in terrific shape, so we're strong and we're executing on our strategy. That's not the case broadly. That said, recently we have seen a strong uptick on the CD3 work. It's probably too early to know exactly how market conditions are going to impact all partners, but I would agree with you that our model provides a way for companies to continue advancing programs, to do that more quickly and more capital efficient. efficiently while preserving their resources. So we typically structure our deals with value sharing based on success in clinical development and ultimately in the approval of therapies. And that lines up well with companies that are cautious about building internal capabilities and taking on you know, the complexity and cost of distributed outsourcing. So we think that could well be a tailwind, but I think it's still a bit early to tell.

All right, that's helpful. Thanks for taking the questions.